Advances in the antiviral treatment of chronic hepatitis C

[3]Armstrong GL, Wasley A, Simard EP, et al.The prevalence of hepati-tis C virus infection in the United States, 1999through2002[J].Ann Intern Med, 2006, (144) :705-714.

[4]Ghany MG, Strader DB, Thomas DL, et al.Diagnosis, manage-ment, and treatment of hepatitis C:an update[J].Hepatology, 2009, 49 (4) :1335-1374.

[5]Seeff LB.Natural history of chronic hepatitis C[J].Hepatology, 2002, 36 (5Suppl1) :S35-S46.

[6]D'souza R, Glynn MJ, Ushiro-Lumb I, et al.Prevalence of hepa-titis C-related cirrhosis in elderly Asian patients infected in child-hood[J].Clin Gastroenterol Hepatol, 2005, 3 (9) :910-917.

[7]Kobayashi S, Takeda T, Enomoto M, et al.Development of hepato-cellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy:a multicenter, retrospective cohort study of1124patients[J].Liver Int, 2007, 27 (2) :186-191.

[8]Gerlach JT, Diepolder HM, Zachoval R, et al.Acute hepatitis C:high rate of both spontaneous and treatment-induced viral clear-ance[J].Gastroenterology, 2003, 125 (1) :80-88.

[9]Veldt BJ, Heathcote EJ, Wedemeyer H, et al.Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis[J].Ann Intern Med, 2007, 147 (10) :677-684.

[10]Deuffic-Burban S, Deltenre P, Louvet A, et al.Impact of viral eradi-cation on mortality related to hepatitis C:a modeling approach in France[J].J Hepatol, 2008, 49 (2) :175-183.

[11]George SL, Bacon BR, Brunt EM, et al.Clinical, virologic, histo-logic, and biochemical outcomes after successful HCV therapy:a5-year follow-up of150patients[J].Hepatology, 2009, 49 (3) :729-738.

[12]European Association for the Study of the Liver.EASL Clinical Practice Guidelines:Management of hepatitis C virus infection[J].J Hepatology, 2011, 55 (2) :245-264.

[13]Mchutchison JG, Lawitz EJ, Shiffman ML, et al.Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection[J].New Engl J Med, 2009 (361) :580-593.

[14]Rumi MG, Alessio aghemo A, Prati GM, et al.Randomized study ofpeginterferon-α2a plus ribavirin vs peginterferon-α2b plus ribavirin in chronic hepatitis C[J].Gastroenterology, 2010, 138 (1) :108-115.

[15]Jacobson IM, Brown RJ, Freilich B, et al.Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C pa-tients:a randomized trial[J].Hepatology, 2007, 4:971-981.

[16]Lam KD, Trinh HN, Do ST, et al.Randomized controlled trial of pegylated interferon-alfa2a and ribavirin in treatment-naive chro-nic hepatitis C genotype6[J].Hepatology, 2010, 52 (5) :1573-1580.

[17]Moreno C, Deltenre P, Pawlotsky JM, et al.Shortened treatment dura-tion in treatment-naive genotype1HCV patients with rapid virological response:a meta-analysis[J].J Hepatol, 2010, 52 (1) :25-31.

[18]Fried MW, Hadziyannis SJ, Shiffman ML, et al.Rapid virological re-sponse is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection[J].J Hepatol, 2011, 55 (1) :69-75.

[19]Kamal SM, El Kamary SS, Shardell MD, et al.Pegylated interferon alpha-2b plus ribavirin in patients with genotype4chronic hepati-tis C:The role of rapid and early virologic response[J].Hepatolo-gy, 2007, 46 (6) :1732-1740.

[20]Berg T, von Wagner M, Nasser S, et al.Extended treatment dura-tion for hepatitis C virus type1:comparing48versus72weeks of peginterferon-alfa-2a plus ribavirin[J].Gastroenterology, 2006, 130 (4) :1086-1097.

[21]Pearlman BL, Ehleben C, Saifee S.Treatment extension to72 weeks of peginterferon and ribavirin in hepatitis c genotype1-in-fected slow responders[J].Hepatology, 2007, 46 (6) :1688-1694.

[22]Ide T, Hino T, Ogata K, et al.A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype1b chronic hepatitis C[J].Am J Gastroenterol, 2009, 104 (1) :70-75.

[23]Mangia A, Minerva N, Bacca D, et al.Individualized treatment duration for hepatitis C genotype1patients:A randomized con-trolled trial[J].Hepatology, 2008, 47 (1) :43-50.

[24]Manns M, Zeuzem S, Sood A, et al.Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype2and3chronic hepatitis C[J].J Hepatol, 2011, 55 (3) :554-563.

[25]Ferenci P, Laferl H, Scherzer TM, et al.Peginterferon alfa-2a and ribavirin for24weeks in hepatitis C type1and4patients with rapid virological response[J].Gastroenterology, 2008, 135 (2) :451-458.

[26]Oze T, Hiramatsu N, Yakushijin T, et al.Indications and limita-tions for aged patients with chronic hepatitis C in pegylated interfer-on alfa-2b plus ribavirin combination therapy[J].J Hepatol, 2011, 54 (4) :604-611.

[27]Jacobson IM, Brown RS Jr, Mccone J, et al.Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype1[J].Hepatology, 2007, 46 (4) :982-990.

[28]Bressler BL, Guindi M, Tomlinson G, et al.High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C[J].Hepatology, 2003, 38 (3) :639-644.

[29]Deltenre P, Louvet A, Lemoine M, et al.Impact of insulin resist-ance on sustained response in HCV patients treated with pegylated interferon and ribavirin:A meta-analysis[J].J Hepatol, 2011, 55 (6) :1187-1194.

[30]Westin J, Lagging M, Dhillon AP, et al.Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection[J].J Viral Hepat, 2007, 14 (1) :29-35.

[31]Schaefer M, Hinzpeter A, Mohmand A, et al.Hepatitis C treatment in"difficult-to-treat"psychiatric patients with pegylated interferon-alpha and ribavirin:response and psychiatric side effects[J].Hepa-tology, 2007, 46 (4) :991-998.

[32]Anand BS, Currie S, Dieperink E, et al.Alcohol use and treatment of hepatitis C virus:results of a National multicenter study[J].Gastroen-terology, 2006, 130 (6) :1607-1616.

[33]Helbling B, Jochum W, Stamenic I, et al.HCV-related advanced fibrosis/cirrhosis:randomized controlled trial of pegylated interferon alpha-2a and ribavirin[J].J Viral Hepat, 2006, 13 (11) :762-769.

[34]Carrat F, Bani-Sadr F, Pol S, et al.Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients:a randomized controlled trial[J].JA-MA, 2004, 292 (23) :2839-2848.

[35]Potthoff A, Wedemeyer H, Boecher WO, et al.The HEP-NET B/C co-infection trial:A prospective multicenter study to investi-gate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection[J].J Hepatol, 2008, 49 (5) :688-694.

[36]Sarrazin C, Susser S, Doehring A, et al.Importance of IL28B gene polymorphisms in hepatitis C virus genotype2and3infected patients[J].J Hepatol, 2011, 54 (3) :415-421.

[37]Ge D, Fellay J, Thompson AJ, et al.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance[J].Na-ture, 2009, 461 (7262) :399-401.

[38]Rauch A, Kutalik Z, Descombes P, et al.Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure:a genome-wide association study[J].Gastroenterology, 2010, 138 (4) :1338-1345.

[39]Thomas DL, Thio CL, Martin MP, et al.Genetic variation in IL28B and spontaneous clearance of hepatitis C virus[J].Nature, 2009, 461 (7265) :798-801.

[40]Suppiah V, Moldovan M, Ahlenstiel G, et al.IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy[J].Nat Genet, 2009, 41:1100-1104.

[41]Kawaoka T, Hayes CN, Ohishi W, et al.Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes2a and2b[J].J Hepatol, 2011, 54 (3) :408-414.

[42]Kurosaki M, Tanaka Y, Nishida N, et al.Pre-treatment predic-tion of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors[J].J Hepatol, 2011, 54 (3) :439-448.

[43]Scherzer TM, Hofer H, Staettermayer AF, et al.Early virologic re-sponse and IL28B polymorphisms in patients with chronic hepatitis C genotype3treated with peginterferon alfa-2a and ribavirin[J].J Hepatol, 2011, 54 (5) :866-871.

[44]Afdhal NH, Mchutchison JG, Zeuzem S, et al.Hepatitis C phar-macogenetics:state of the art in2010[J].Hepatology, 2011, 53 (1) :336-345.

[45]Tillmann HL, Patel K, Muir AJ, et al.Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C[J].J Hepatol, 2011, 55 (6) :1195-1200.

[46]O'brien TR.Interferon-alfa, interferon-λand hepatitis C[J].nature genetics, 2009, 41 (10) :1049-1050.

[47]Langhans B, Kupfer B, Braunschweiger I, et al.Interferon-lamb-da serum levels in hepatitis C[J].J Hepatol, 2011, 54 (5) :859-865.

[48]Abe H, Hayes CN, Ochi H, et al.IL28variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy[J].J Hepatol, 2011, 54 (6) :1094-1101.

[49]Zhang L, Jilg N, Shao RX, et al.IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway[J].J Hepatol, 2011, 55 (2) :289-298.

[50]Pockros PJ.New direct-acting antivirals in the development for hepatitis C virus infection[J].Therap Adv Gastroenterol, 2010, 3 (3) :191-202.

[51]Jacobson IM, McHutchison JG, Dusheiko GM, et al.Telaprevir in combination with peginterferon and ribavirin in genotype1HCV treatment-naive patients:final results of Phase3ADVANCE study[J].Hepatology2010;52:427A.

[52]Sherman KE, Flamm SL, Afdhal NH, et al.Telaprevir in combination with peginterferon alfa2b and ribavirin for24or48weeks in treatment-naive genotype1HCV patients who achieved an extended rapid viral re-sponse:final results of Phase3ILLUMINATE study[J].Hepatology, 2010, 52:401A.

[53]Zeuzem S, Andreone P, Pol S, et al.Realize trial resuilts:Telapla-previr-based regimen for genotype1hepatitis C virus infection in patients with prior null response, partial response or relapse to Peginterferon/ribavirin[J].J Hepatol, 2011, 54 (Suppl) :S3A.

[54]Bacon BR, Gordon SC, Lawitz E, et al.HCV RESPOND-2final results:high sustained virologic response among genotype1previous nonresponders and relapsers to peginterferon/ribavirin when retrea-ted with boceprevir plus PegIntron/ribavirin[J].Hepatology, 2010, 52:430A.

[55]Poordad F, Mccone J, Bacon BR, et al.Boceprevir (BOC) combined with peginterferon alfa-2b/ribavirin (P/R) for treatment-naive pa-tients with hepatitis C (HCV) genotype1:SPRINT-2final results[J].Hepatology, 2010, 52:402A.

[56]Bruno S, Vierling JM, Esteban R, et al.Boceprevir in addition to atandasd of care enhanced SVR in hepatitis C virus (HCV) genotype-1with advanced fibrosis/cirrhosis:Subgroup analysis of SPRINT-2and RESPOND-2studies[J].J Hepatol, 2011, 54 (Suppl) :S4A.

[57]Ghany MG, Nelson DR, Strader DB, et al.An update on treatment of genotype1chronic hepatitis C virus infection:2011practice guideline by the American Association for the Study of Liver Disea-ses[J].Hepatology, 2011, 54 (4) :1433-1444.

[58]Ohara E, Hiraga N, Imamura M, et al.Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination thera-py in human hepatocyte chimeric mice[J].J Hepatol, 2011, 54 (5) :872-878.

[59]Bisceglie AD, Nelson DR, Gane E, et al.1363VX-222with tvralone or in combination with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis c:zenith study in-terim results[J].J Hepatol, 2011, 54 (Suppl) :S540.

[60]Lok A, Gardiner D, Lawitz E, et al.1356quadruple therapy with bms-790052, bms-650032and peg-ifn/rbv for24weeks results in100%svr12in hcv genotype1null responders[J].J Hepatol, 2011, 54 (Suppl) :S536.

[61]Stefan zeuzem ST, Peter angus PA.Efficacy of the protease inhibi-tor BI201335, polymerase inhibitor BI207127, and ribavirin in pa-tients with chronic HCV infection[J].Gastroenterology, 2011, 141 (6) :2047-2055.

Relative Articles

[1]	Lixian WU, Weiqiang ZHENG, Huanqin HAN. Effect of different antiviral drugs in reducing the risk of hepatitis B virus-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(5): 1165-1168. doi: 10.3969/j.issn.1001-5256.2022.05.040
[2]	Mingyang FENG, Hui WANG. Selection of antiviral drugs for patients with hepatitis B virus-associated hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(11): 2452-2456. doi: 10.3969/j.issn.1001-5256.2022.11.004
[3]	Qian ZHU, Mingyuan ZHANG, Junqi NIU. Advances in direct-acting antiviral therapy for liver transplant recipients with HCV-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(10): 2444-2447. doi: 10.3969/j.issn.1001-5256.2021.10.039
[4]	LIU YuWei, JIN JingLan, REN TianYi, GAO XiuZhu, LI Jie, ZHU Qing, NIU JunQi. Effect of direct-acting antiviral on the recurrence hepatitis C virus-related hepatocellular carcinoma after curative treatment: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(12): 2714-2719. doi: 10.3969/j.issn.1001-5256.2020.12.015
[5]	Chen JianHong, Xu XiaoYuan. Selection of direct-acting antiviral agents in treatment of chronic hepatitis C patients with renal dysfunction[J]. Journal of Clinical Hepatology, 2018, 34(2): 251-254. doi: 10.3969/j.issn.1001-5256.2018.02.007
[6]	An ZiYing, Ding Yang, Dou XiaoGuang. Selection and evaluation of treatment regimens with direct-acting antiviral agents for patients with chronic hepatitis C in the real world in China[J]. Journal of Clinical Hepatology, 2018, 34(2): 233-237. doi: 10.3969/j.issn.1001-5256.2018.02.003
[7]	Wang MengLan, Tang Hong. Drug-drug interaction of direct-acting antivirals in treatment of chronic hepatitis C[J]. Journal of Clinical Hepatology, 2018, 34(2): 229-232. doi: 10.3969/j.issn.1001-5256.2018.02.002
[8]	Zhang Xi, Li YongGuo. Current status of the application of direct-acting antiviral agents in treatment of chronic hepatitis C and existing problems[J]. Journal of Clinical Hepatology, 2018, 34(4): 853-857. doi: 10.3969/j.issn.1001-5256.2018.04.034
[9]	Chen XinYue, Liu YaLi, Ren Shan. Value of direct-acting antivirals combined with PR regimen (PEG-IFN combined with ribavirin) in the new era of antiviral therapy for hepatitis C[J]. Journal of Clinical Hepatology, 2017, 33(6): 1063-1066. doi: 10.3969/j.issn.1001-5256.2017.06.009
[10]	Ceng Qun, Jie ShengHua. Research advances in antiviral drugs and their treatment regimens in chronic hepatitis C[J]. Journal of Clinical Hepatology, 2017, 33(11): 2200-2204. doi: 10.3969/j.issn.1001-5256.2017.11.033
[11]	Ceng QingLei, Yu ZuJiang. Whether antiviral therapy can reduce the incidence of hepatocellular carcinoma in patients with chronic HCV infection[J]. Journal of Clinical Hepatology, 2017, 33(6): 1075-1078. doi: 10.3969/j.issn.1001-5256.2017.06.011
[12]	Wen XiaoYu, Niu JunQi. Mechanism of action of direct-acting antiviral agents in treatment of chronic hepatitis C[J]. Journal of Clinical Hepatology, 2016, 32(9): 1699-1705. doi: 10.3969/j.issn.1001-5256.2016.09.013
[13]	Zhang Yu, Cao Ying, Zhang RenWen, Zhang XiaXia, Lu HaiYing, Wu ChiHong, Huo Na, Yu Min, Liu Dan, Xu XiaoYuan. Natural resistance mutations to direct- acting antiviral agents in interferon / ribavirin treatment- experienced and treatment- nave patients with chronic hepatitis C in Beijing,China[J]. Journal of Clinical Hepatology, 2016, 32(4): 711-715. doi: 10.3969/j.issn.1001-5256.2016.04.020
[14]	Li Long, Wu ZhangHui, Wei Jia. Research progress in association between interleukin 28B gene polymorphism and hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(11): 1916-1920. doi: 10.3969/j.issn.1001-5256.2015.11.040
[15]	Zhang Can, Wan Hui, Chen Hong, Zhang Kai. Research progress in interleukin 28B polymorphisms in infection and treatment of chronic hepatitis B virus[J]. Journal of Clinical Hepatology, 2015, 31(4): 622-625. doi: 10.3969/j.issn.1001-5256.2015.04.036
[16]	Shen WenJuan, Ha MingHao. Research advances in associations between IL28B polymorphisms and chronic hepatitis B /C virus infection[J]. Journal of Clinical Hepatology, 2014, 30(10): 1087-1090. doi: 10.3969/j.issn.1001-5256.2014.10.028
[17]	Tan GuoLei, Sun Mei, Wang JianFang, Wu XuPing. Relationship between IL- 28B polymorphisms and susceptibility to hepatitis C among Han population in Jiangsu Province, China[J]. Journal of Clinical Hepatology, 2014, 30(6): 514-517. doi: 10.3969/j.issn.1001-5256.2014.06.009
[18]	Zhou Li, Qie ChunHua, Guo Jie, Lu Wei, Wang Yi, Gao Min, Lu ChengZhen, Han Xu, Zhai Lu. Association between the type Ⅰinterferon receptor promoter gene and treatment response to antivirus in patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2012, 28(5): 352-355.
[19]	Zuo WeiZe, Xu ChunMei, Shen LanChao. Changes in serum level of interleukin-32 and interleukin-6 in patients with chronic hepatitis B virus infection and its clinical significance[J]. Journal of Clinical Hepatology, 2011, 27(4): 408-410+413.
[20]	Shi XiaoDong, Jiang Jing, Niu JunQi. Association of interleukin 28B(IL28B) polymorphisms with the outcomes of HCV infection[J]. Journal of Clinical Hepatology, 2011, 27(1): 28-31.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2908) PDF downloads(760)

Advances in the antiviral treatment of chronic hepatitis C

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Advances in the antiviral treatment of chronic hepatitis C

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content